John P. Leonard

Cornell University — United States

Medicine · Health Sciences

32h-index6.1kcitations180works0.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(38), CAR-T cell therapy research(21), Cytokine Signaling Pathways and Interactions(20), Crystallization and Solubility Studies(16), X-ray Diffraction in Crystallography(16)

Publications180 total

Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents
Leukemia & lymphoma/Leukemia and lymphoma·2025
Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma
Blood·2024· 1 citedOpen Access
Nodal T-Cell Lymphoma Transdifferentiated from Mantle Cell Lymphoma with Epstein-Barr Virus Infection
Pathobiology·2024Open Access
Racial Disparities in Endometrial Cancer Clinical Trial Representation
American Journal of Clinical Oncology·2024· 1 citedOpen Access
Data from Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas
2023Open Access
Supplementary Table S3 from Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S <i>BTK</i> Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
2023Open Access
Table S2 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma
2023Open Access
Supplementary Table S8 from BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells
2023Open Access
Figures S1 - S4 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma
2023Open Access
Supplementary Table S1 from Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S <i>BTK</i> Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
2023Open Access
Supplementary Table S2 from Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S <i>BTK</i> Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
2023Open Access
Supplementary Tables from Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
2023Open Access
Figure S5 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma
2023Open Access
Supplementary Figure S1 from Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S <i>BTK</i> Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
2023Open Access
Figure S6 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma
2023Open Access
Supplementary Data from Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas
2023Open Access
Figure S5 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma
2023Open Access
Figures S7 - S9 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma
2023Open Access
Data from Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas
2023Open Access
Data from Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S <i>BTK</i> Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
2023Open Access
page 1 of 9Next →

Frequent Co-authors

M. L. Cuzner(10), K E Waldburger(7), Samuel J. Goldman(7), Kyriaki Dunussi‐Joannopoulos(6), Robert G. Schaub(5), Sharon Hunter(4), Joy Miyashiro(4), Suzana Marušić(4), Kathlene Runyon(4), Vincent Ling(3), Mary Collins(3), Paresh Thakker(3), Jeffrey W. Pelker(3), Adrian K. Hewson(3), Terence Smith(3), Krystyna Zuberek(3), Robert G. Hawley(3), Jamie Erickson(3), F.J. MacKenzie(3), Michael J. Aziz(3)